{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:00:53Z","timestamp":1790744453450,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00125-021-05497-1","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T12:08:19Z","timestamp":1625054899000},"page":"1949-1962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors"],"prefix":"10.1007","volume":"64","author":[{"given":"Donna Shu-Han","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Kuang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jone","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"5497_CR1","volume-title":"Global report on diabetes","year":"2016","unstructured":"Roglic G, Varghese C, Riley L, Harvey A (eds) (2016) Global report on diabetes. World Health Organization, Geneva, Switzerland"},{"issue":"8","key":"5497_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/CIR.0000000000000230","volume":"132","author":"CS Fox","year":"2015","unstructured":"Fox CS, Golden SH, Anderson C et al (2015) Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 132(8):691\u2013718. https:\/\/doi.org\/10.1161\/CIR.0000000000000230","journal-title":"Circulation."},{"key":"5497_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/5584_2020_514","volume":"1307","author":"F Maranta","year":"2021","unstructured":"Maranta F, Cianfanelli L, Cianflone D (2021) Glycaemic control and vascular complications in diabetes mellitus type 2. Adv Exp Med Biol 1307:129\u2013152. https:\/\/doi.org\/10.1007\/5584_2020_514","journal-title":"Adv Exp Med Biol"},{"issue":"16","key":"5497_CR4","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.jacc.2020.02.056","volume":"75","author":"T Wilcox","year":"2020","unstructured":"Wilcox T, De Block C, Schwartzbard AZ, Newman JD (2020) Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC focus seminar. J Am Coll Cardiol 75(16):1956\u20131974. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.056","journal-title":"J Am Coll Cardiol"},{"key":"5497_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ahj.2016.09.002","volume":"184","author":"JD Newman","year":"2017","unstructured":"Newman JD, Rockman CB, Kosiborod M et al (2017) Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease. Am Heart J 184:114\u2013120. https:\/\/doi.org\/10.1016\/j.ahj.2016.09.002","journal-title":"Am Heart J"},{"issue":"6","key":"5497_CR6","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.2337\/dc13-2432","volume":"37","author":"B Shah","year":"2014","unstructured":"Shah B, Rockman CB, Guo Y et al (2014) Diabetes and vascular disease in different arterial territories. Diabetes Care 37(6):1636\u20131642. https:\/\/doi.org\/10.2337\/dc13-2432","journal-title":"Diabetes Care"},{"issue":"7","key":"5497_CR7","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2337\/diacare.27.7.1591","volume":"27","author":"EW Gregg","year":"2004","unstructured":"Gregg EW, Sorlie P, Paulose-Ram R et al (2004) Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 27(7):1591\u20131597. https:\/\/doi.org\/10.2337\/diacare.27.7.1591","journal-title":"Diabetes Care"},{"issue":"9","key":"5497_CR8","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","volume":"116","author":"MH Criqui","year":"2015","unstructured":"Criqui MH, Aboyans V (2015) Epidemiology of peripheral artery disease. Circ Res 116(9):1509\u20131526. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303849","journal-title":"Circ Res"},{"issue":"24","key":"5497_CR9","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"ADVANCE Collaborative Group, Patel A, MacMahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560\u20132572. https:\/\/doi.org\/10.1056\/NEJMoa0802987","journal-title":"N Engl J Med"},{"issue":"2","key":"5497_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa0808431","journal-title":"N Engl J Med"},{"issue":"24","key":"5497_CR11","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"ACCORD Study Group, Gerstein HC, Miller ME et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545\u20132559. https:\/\/doi.org\/10.1056\/NEJMoa0802743","journal-title":"N Engl J Med"},{"issue":"3","key":"5497_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373(3):232\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa1501352","journal-title":"N Engl J Med"},{"issue":"1","key":"5497_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321(1):69\u201379. https:\/\/doi.org\/10.1001\/jama.2018.18269","journal-title":"JAMA."},{"key":"5497_CR14","doi-asserted-by":"publisher","unstructured":"Rosenstock J, Kahn SE, Johansen OE et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2019.13772","DOI":"10.1001\/jama.2019.13772"},{"issue":"14","key":"5497_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317\u20131326. https:\/\/doi.org\/10.1056\/NEJMoa1307684","journal-title":"N Engl J Med"},{"issue":"14","key":"5497_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327\u20131335. https:\/\/doi.org\/10.1056\/NEJMoa1305889","journal-title":"N Engl J Med"},{"issue":"13","key":"5497_CR17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377(13):1228\u20131239. https:\/\/doi.org\/10.1056\/NEJMoa1612917","journal-title":"N Engl J Med"},{"issue":"4","key":"5497_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"issue":"19","key":"5497_CR19","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"issue":"9","key":"5497_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381(9):841\u2013851. https:\/\/doi.org\/10.1056\/NEJMoa1901118","journal-title":"N Engl J Med"},{"issue":"23","key":"5497_CR21","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247\u20132257. https:\/\/doi.org\/10.1056\/NEJMoa1509225","journal-title":"N Engl J Med"},{"issue":"10193","key":"5497_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet."},{"issue":"10157","key":"5497_CR23","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519\u20131529. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X","journal-title":"Lancet."},{"issue":"22","key":"5497_CR24","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"4","key":"5497_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"15","key":"5497_CR26","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383(15):1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"issue":"7","key":"5497_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"10","key":"5497_CR28","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2337\/dc18-1094","volume":"41","author":"K Dhatariya","year":"2018","unstructured":"Dhatariya K, Bain SC, Buse JB et al (2018) The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial. Diabetes Care 41(10):2229\u20132235. https:\/\/doi.org\/10.2337\/dc18-1094","journal-title":"Diabetes Care"},{"key":"5497_CR29","doi-asserted-by":"publisher","first-page":"e2018062","DOI":"10.4178\/epih.e2018062","volume":"40","author":"L-Y Lin","year":"2018","unstructured":"Lin L-Y, Warren-Gash C, Smeeth L, Chen P-C (2018) Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol Health 40:e2018062. https:\/\/doi.org\/10.4178\/epih.e2018062","journal-title":"Epidemiol Health"},{"key":"5497_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"C-Y Hsieh","year":"2019","unstructured":"Hsieh C-Y, Su C-C, Shao S-C et al (2019) Taiwan\u2019s National Health Insurance Research Database: past and future. Clin Epidemiol 11:349\u2013358. https:\/\/doi.org\/10.2147\/CLEP.S196293","journal-title":"Clin Epidemiol"},{"issue":"9","key":"5497_CR31","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamainternmed.2015.3540","volume":"175","author":"AW Hsing","year":"2015","unstructured":"Hsing AW, Ioannidis JPA (2015) Nationwide population science: lessons from the Taiwan national health insurance research database. JAMA Intern Med 175(9):1527\u20131529. https:\/\/doi.org\/10.1001\/jamainternmed.2015.3540","journal-title":"JAMA Intern Med"},{"key":"5497_CR32","doi-asserted-by":"publisher","first-page":"e009724","DOI":"10.1161\/JAHA.118.009724","volume":"7","author":"JA Mustapha","year":"2018","unstructured":"Mustapha JA, Katzen BT, Neville RF et al (2018) Determinants of long-term outcomes and costs in the management of critical limb ischemia: a population-based cohort study. J Am Heart Assoc 7:e009724. https:\/\/doi.org\/10.1161\/JAHA.118.009724","journal-title":"J Am Heart Assoc"},{"key":"5497_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/1358863X14559589","volume":"19","author":"W Bekwelem","year":"2014","unstructured":"Bekwelem W, Bengtson LG, Oldenburg NC et al (2014) Development of administrative data algorithms to identify patients with critical limb ischemia. Vasc Med 19:483\u2013490. https:\/\/doi.org\/10.1177\/1358863X14559589","journal-title":"Vasc Med"},{"issue":"6","key":"5497_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2188\/jea.je20140076","volume":"24","author":"C-L Cheng","year":"2014","unstructured":"Cheng C-L, Lee C-H, Chen P-S, Li Y-H, Lin S-J, Yang Y-HK (2014) Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J Epidemiol 24(6):500\u2013507. https:\/\/doi.org\/10.2188\/jea.je20140076","journal-title":"J Epidemiol"},{"issue":"3","key":"5497_CR35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jfma.2013.09.009","volume":"114","author":"C-Y Hsieh","year":"2015","unstructured":"Hsieh C-Y, Chen C-H, Li C-Y, Lai M-L (2015) Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc 114(3):254\u2013259. https:\/\/doi.org\/10.1016\/j.jfma.2013.09.009","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"5497_CR36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/pds.2087","volume":"20","author":"C-L Cheng","year":"2011","unstructured":"Cheng C-L, Kao Y-HY, Lin S-J, Lee C-H, Lai ML (2011) Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 20(3):236\u2013242. https:\/\/doi.org\/10.1002\/pds.2087","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5497_CR37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijcard.2015.07.075","volume":"201","author":"C-L Cheng","year":"2015","unstructured":"Cheng C-L, Chien H-C, Lee C-H, Lin S-J, Yang Y-HK (2015) Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int J Cardiol 201:96\u2013101. https:\/\/doi.org\/10.1016\/j.ijcard.2015.07.075","journal-title":"Int J Cardiol"},{"issue":"12","key":"5497_CR38","doi-asserted-by":"publisher","first-page":"e112257","DOI":"10.1371\/journal.pone.0112257","volume":"9","author":"C-S Wu","year":"2014","unstructured":"Wu C-S, Lai M-S, Gau SS-F, Wang S-C, Tsai H-J (2014) Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan. PLoS One 9(12):e112257. https:\/\/doi.org\/10.1371\/journal.pone.0112257","journal-title":"PLoS One"},{"issue":"1","key":"5497_CR39","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1186\/s12913-016-1769-8","volume":"16","author":"S-F Sung","year":"2016","unstructured":"Sung S-F, Hsieh C-Y, Lin H-J et al (2016) Validity of a stroke severity index for administrative claims data research: a retrospective cohort study. BMC Health Serv Res 16(1):509. https:\/\/doi.org\/10.1186\/s12913-016-1769-8","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"5497_CR40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S2213-8587(16)30010-9","volume":"4","author":"EW Gregg","year":"2016","unstructured":"Gregg EW, Sattar N, Ali MK (2016) The changing face of diabetes complications. Lancet Diabetes Endocrinol 4(6):537\u2013547. https:\/\/doi.org\/10.1016\/S2213-8587(16)30010-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"5497_CR41","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.2337\/dc10-1213","volume":"33","author":"LA Lavery","year":"2010","unstructured":"Lavery LA, Hunt NA, Ndip A, Lavery DC, Van Houtum W, Boulton AJM (2010) Impact of chronic kidney disease on survival after amputation in individuals with diabetes. Diabetes Care 33(11):2365\u20132369. https:\/\/doi.org\/10.2337\/dc10-1213","journal-title":"Diabetes Care"},{"issue":"3","key":"5497_CR42","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.amjmed.2016.10.016","volume":"130","author":"C-C Chang","year":"2017","unstructured":"Chang C-C, Chen Y-T, Hsu C-Y et al (2017) Dipeptidyl peptidase-4 inhibitors, peripheral arterial disease, and lower extremity amputation risk in diabetic patients. Am J Med 130(3):348\u2013355. https:\/\/doi.org\/10.1016\/j.amjmed.2016.10.016","journal-title":"Am J Med"},{"key":"5497_CR43","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365. https:\/\/doi.org\/10.1136\/bmj.k4365","journal-title":"BMJ."},{"key":"5497_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jss.2016.09.024","volume":"208","author":"J-N Roan","year":"2017","unstructured":"Roan J-N, Cheng H-N, Young C-C et al (2017) Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing. J Surg Res 208:93\u2013103. https:\/\/doi.org\/10.1016\/j.jss.2016.09.024","journal-title":"J Surg Res"},{"issue":"4","key":"5497_CR45","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/1479164113481817","volume":"10","author":"T Gaspari","year":"2013","unstructured":"Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE (2013) The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-\/-) mouse model. Diab Vasc Dis Res 10(4):353\u2013360. https:\/\/doi.org\/10.1177\/1479164113481817","journal-title":"Diab Vasc Dis Res"},{"issue":"16","key":"5497_CR46","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"L Bowman","year":"2018","unstructured":"ASCEND Study Collaborative Group, Bowman L, Mafham M et al (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 379(16):1529\u20131539. https:\/\/doi.org\/10.1056\/NEJMoa1804988","journal-title":"N Engl J Med"},{"issue":"25","key":"5497_CR47","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","volume":"138","author":"S Verma","year":"2018","unstructured":"Verma S, Poulter NR, Bhatt DL et al (2018) Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation 138(25):2884\u20132894. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034516","journal-title":"Circulation."},{"issue":"1","key":"5497_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2012.11.009","volume":"100","author":"S Herzlinger","year":"2013","unstructured":"Herzlinger S, Horton ES (2013) Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes. Diabetes Res Clin Pract 100(1):1\u201310. https:\/\/doi.org\/10.1016\/j.diabres.2012.11.009","journal-title":"Diabetes Res Clin Pract"},{"key":"5497_CR49","doi-asserted-by":"publisher","first-page":"154343","DOI":"10.1016\/j.metabol.2020.154343","volume":"111","author":"A Sachinidis","year":"2020","unstructured":"Sachinidis A, Nikolic D, Stoian AP et al (2020) Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metab Clin Exp 111:154343. https:\/\/doi.org\/10.1016\/j.metabol.2020.154343","journal-title":"Metab Clin Exp"},{"issue":"5","key":"5497_CR50","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1055\/s-0040-1709711","volume":"120","author":"D Pastori","year":"2020","unstructured":"Pastori D, Farcomeni A, Milanese A et al (2020) Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost 120(5):866\u2013875. https:\/\/doi.org\/10.1055\/s-0040-1709711","journal-title":"Thromb Haemost"},{"issue":"1","key":"5497_CR51","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jacl.2017.11.006","volume":"12","author":"Y Hasegawa","year":"2018","unstructured":"Hasegawa Y, Hori M, Nakagami T, Harada-Shiba M, Uchigata Y (2018) Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. J Clin Lipidol 12(1):62\u201369.e1","journal-title":"J Clin Lipidol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-021-05497-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-021-05497-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-021-05497-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T20:02:23Z","timestamp":1656532943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-021-05497-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["5497"],"URL":"https:\/\/doi.org\/10.1007\/s00125-021-05497-1","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}